| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |